Pharmacogénomique de l'asthme

Pharmacogenomics attempts to explain some of the variability of the response to medications by individual genetic variability. Regarding asthma, it is known that there is individual variability in the response to the three most important classes of anti-asthmatic mediations, namely, inhaled β2 gonists, anti-leucotrienes and inhaled corticosteroids. For each therapeutic class, there is evidence that the existence of polymorphisms in certain candidate genes, for example, the β2-receptor, the 5-lipoxygenase gene promoter and one of the corticotrophin releasing factor receptors, is associated with the response to these drugs. We anticipate that the results of ongoing studies of the many polymorphisms located on the different genes of the metabolic pathways involved in the efficacy as well as the adverse effects of these drugs will lead to better adaptation to individual requirements in therapeutic management.